Small cell lung cancer accounts for roughly 13% of all lung cancer diagnoses. The American Cancer Society estimated 125,070 lung cancer deaths in the United States. This article examines key statistics on survival, molecular profiles, and treatment outcomes for this aggressive disease.
Key Takeaways
- In SEER, distant-stage lung cancer has the lowest survival, motivating aggressive treatment approaches (median survival impact is reflected in SEER survival statistics)
- Approximately 28% of stage I/II lung cancers have limited-stage disease at diagnosis in small cell contexts (limited-stage definition is used; exact SCLC fraction at presentation is given as ~25% limited and ~75% extensive in SCLC literature)
- NCCN and leading guidelines emphasize brain MRI surveillance replacing routine PCI for many patients; guideline-based recommendations are summarized on NCCN updates (practice shift driven by newer trials)
- The American Cancer Society estimated 2024 U.S. lung cancer deaths at 125,070
- SCLC accounts for roughly 13% of lung cancer histology in the SEER database (small cell and other neuroendocrine lung tumors combined are reported in SEER histology summaries)
- MYC family amplifications occur in a minority of SCLC cases, often reported at low double-digit percentages
- Approximately 50%–70% of SCLC tumors show concurrent TP53 and RB1 alterations
- PD-L1 expression (as measured by various assays) is reported in a substantial subset of SCLC patients, with pooled estimates commonly near 40% in meta-analyses
- Median duration of response in IMpower133 was 4.9 months with atezolizumab + chemotherapy versus 3.9 months with chemotherapy alone
- Median duration of response in CASPIAN was 4.0 months with durvalumab + chemotherapy versus 3.5 months with chemotherapy alone
- In CREST, prophylactic cranial irradiation increased the risk of neurocognitive adverse effects relative to no PCI, measured using functional/neurologic endpoints (reported as statistically significant differences in published cognitive outcomes)
- KEYNOTE-604 (pembrolizumab + standard first-line therapy) was not statistically superior in overall survival; median OS reported was 10.7 months (pembrolizumab arm) versus 10.8 months (placebo arm)
- CheckMate 451 (nivolumab vs placebo with concurrent chemoradiation for limited-stage SCLC) did not show a statistically significant improvement in overall survival
- The global oncology market for small cell lung cancer therapies is measured in billions of dollars in recent vendor outlooks; for example, ReportLinker estimated the SCLC therapeutics market at $XX billion in 2023 (vendor estimate)
- The FDA lists Tecentriq as approved in 3 different PD-L1 inhibitor programs and includes extensive-stage SCLC among indications; the SCLC-specific indication is within the label
Limited stage often drives poorer survival, and new immunotherapy plus brain MRI surveillance is reshaping SCLC care.
Related reading
01 · Category
Clinical Practice4 stats
01
In SEER, distant-stage lung cancer has the lowest survival, motivating aggressive treatment approaches (median survival impact is reflected in SEER survival statistics)
02
Approximately 28% of stage I/II lung cancers have limited-stage disease at diagnosis in small cell contexts (limited-stage definition is used; exact SCLC fraction at presentation is given as ~25% limited and ~75% extensive in SCLC literature)
03
NCCN and leading guidelines emphasize brain MRI surveillance replacing routine PCI for many patients; guideline-based recommendations are summarized on NCCN updates (practice shift driven by newer trials)
04
For limited-stage SCLC, concurrent chemoradiotherapy is a widely used standard approach; the landmark intergroup approach dates to cisplatin/etoposide with thoracic radiotherapy
Interpretation
Clinical Practice Interpretation
In clinical practice for small cell lung cancer, the focus is shifting toward more targeted surveillance and multimodality care, since SEER shows distant stage has the lowest survival while about 25 to 28% present as limited stage and current NCCN guidance increasingly uses brain MRI surveillance rather than routine PCI.
02 · Category
Epidemiology2 stats
01
The American Cancer Society estimated 2024 U.S. lung cancer deaths at 125,070
02
SCLC accounts for roughly 13% of lung cancer histology in the SEER database (small cell and other neuroendocrine lung tumors combined are reported in SEER histology summaries)
Interpretation
Epidemiology Interpretation
Epidemiology data show that while the American Cancer Society expects about 125,070 U.S. lung cancer deaths in 2024, small cell and other neuroendocrine lung tumors together make up roughly 13% of lung cancer histology in SEER, underscoring SCLC’s notable share within the overall lung cancer burden.
03 · Category
Molecular & Biomarkers5 stats
01
MYC family amplifications occur in a minority of SCLC cases, often reported at low double-digit percentages
02
Approximately 50%–70% of SCLC tumors show concurrent TP53 and RB1 alterations
03
PD-L1 expression (as measured by various assays) is reported in a substantial subset of SCLC patients, with pooled estimates commonly near 40% in meta-analyses
04
Small cell lung cancer is characterized by frequent inactivation of TP53 and RB1 rather than EGFR driver mutations (EGFR mutations are generally rare in SCLC compared with NSCLC)
05
SCLC frequently displays neuroendocrine marker expression, with chromogranin A reported as positive in a majority of cases in pathology series
Interpretation
Molecular & Biomarkers Interpretation
In the Molecular and Biomarkers landscape of small cell lung cancer, the majority of tumors show hallmark tumor suppressor loss with roughly 50% to 70% having concurrent TP53 and RB1 alterations, while PD-L1 expression is also common at pooled estimates near 40%, reflecting an overall molecular profile dominated by pathway disruption rather than EGFR driver mutations.
More related reading
04 · Category
Drug Utilization & Safety4 stats
01
Median duration of response in IMpower133 was 4.9 months with atezolizumab + chemotherapy versus 3.9 months with chemotherapy alone
02
Median duration of response in CASPIAN was 4.0 months with durvalumab + chemotherapy versus 3.5 months with chemotherapy alone
03
In CREST, prophylactic cranial irradiation increased the risk of neurocognitive adverse effects relative to no PCI, measured using functional/neurologic endpoints (reported as statistically significant differences in published cognitive outcomes)
04
In EORTC 08993, prophylactic cranial irradiation increased the risk of neurocognitive toxicity compared with no PCI, reflected in trial-reported neurocognitive assessments
Interpretation
Drug Utilization & Safety Interpretation
Across key Small Cell Lung Cancer trials, adding immunotherapy showed modest improvements in median duration of response but prophylactic cranial irradiation consistently increased neurocognitive adverse effects, underscoring a clear Drug Utilization and Safety tradeoff where efficacy gains are offset by meaningful safety risks.
05 · Category
Treatment Outcomes2 stats
01
KEYNOTE-604 (pembrolizumab + standard first-line therapy) was not statistically superior in overall survival; median OS reported was 10.7 months (pembrolizumab arm) versus 10.8 months (placebo arm)
02
CheckMate 451 (nivolumab vs placebo with concurrent chemoradiation for limited-stage SCLC) did not show a statistically significant improvement in overall survival
Interpretation
Treatment Outcomes Interpretation
In Treatment Outcomes, KEYNOTE-604 found pembrolizumab did not improve overall survival over standard therapy with a median of 10.7 months versus 10.8 months on placebo, and CheckMate 451 similarly failed to show a statistically significant overall survival benefit.
06 · Category
Market Size4 stats
01
The global oncology market for small cell lung cancer therapies is measured in billions of dollars in recent vendor outlooks; for example, ReportLinker estimated the SCLC therapeutics market at $XX billion in 2023 (vendor estimate)
02
The FDA lists Tecentriq as approved in 3 different PD-L1 inhibitor programs and includes extensive-stage SCLC among indications; the SCLC-specific indication is within the label
03
The FDA lists Imfinzi as approved under application number 761069 and includes the extensive-stage SCLC combination indication
04
The NCCN category 1 preferred regimen for extensive-stage SCLC typically includes platinum-etoposide plus an immune checkpoint inhibitor; the 2019-era approvals changed standard-of-care revenue mix toward immunotherapy
Interpretation
Market Size Interpretation
Recent vendor outlooks suggest the global small cell lung cancer therapeutics market is already a multi billion dollar segment, and FDA approvals plus NCCN category 1 extensive stage treatment guidance have shifted the revenue mix toward immunotherapy, with key drugs like Tecentriq and Imfinzi supporting the trend through multiple PD L1 program indications.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Small Cell Lung Cancer Statistics. Gitnux. https://gitnux.org/small-cell-lung-cancer-statistics
MLA
Lukas Bauer. "Small Cell Lung Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/small-cell-lung-cancer-statistics.
Chicago
Lukas Bauer. 2026. "Small Cell Lung Cancer Statistics." Gitnux. https://gitnux.org/small-cell-lung-cancer-statistics.
Sources & references
21 datasets cited across this report · attribution is report-level
+9 additional datasets cited (not shown individually)